Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma

Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma

Afficher d'autres versions (2)

Détails bibliographiques
Auteurs principaux:	Druce, M, Chung, T, Grozinsky-Glasberg, S, Gross, D, Grossman, AB
Format:	Journal article
Langue:	English
Publié:	2012

Documents similaires

Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma.
par: Druce, M, et autres
Publié: (2012)

Preliminary Report of the Use of Everolimus in a Patient with Progressive Medullary Thyroid Carcinoma
par: Druce, M, et autres
Publié: (2010)

The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
par: Grozinsky-Glasberg, S, et autres
Publié: (2010)

The Rapamycin Derivative RAD001 (Everolimus) Inhibits Cell Proliferation and Interacts with the Akt-mTOR-p70S6K Pathway in Human Medullary Thyroid Carcinoma Cells
par: Grozinsky-Glasberg, S, et autres
Publié: (2009)

IGF-1 influences Everolimus activity in medullary thyroid carcinoma
par: Erica eGentilin, et autres
Publié: (2015-05-01)

Everolimus therapy for progressive adrenocortical cancer
par: Fraenkel, M, et autres
Publié: (2013)

Everolimus therapy for progressive adrenocortical cancer.
par: Fraenkel, M, et autres
Publié: (2013)

Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).
par: Druce, MR, et autres
Publié: (2009)

The Global mTOR Inhibitor Torin1 Is More Effective than the mTORC1 Inhibitor, Everolimus, Alone or in Combination with Histone Deacetylase Inhibitors, in Suppressing Neuroendocrine Tumor Cell Proliferation
par: Grozinsky-Glasberg, S, et autres
Publié: (2011)

MEDULLARY THYROID CARCINOMA
par: V. S. Medvedev, et autres
Publié: (2015-04-01)

Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
par: Gupta, P, et autres
Publié: (2014)

Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial
par: T. C. Schneider, et autres
Publié: (2015-01-01)

The role of somatostatin analogues in the treatment of neuroendocrine tumours.
par: Grozinsky-Glasberg, S, et autres
Publié: (2008)

The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report
par: Gawlik Tomasz, et autres
Publié: (2010-11-01)

Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
par: Sen Gupta, P, et autres
Publié: (2014)

Hashimoto's Thyroiditis and Medullary Carcinoma of Thyroid
par: Senjuti Dasgupta, et autres
Publié: (2014-06-01)

Medullary thyroid cancer: molecular biology and novel molecular therapies.
par: Cakir, M, et autres
Publié: (2009)

An update on medullary carcinoma thyroid
par: Mithun Raam, et autres
Publié: (2019-01-01)

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
par: Chan, H, et autres
Publié: (2010)

Metastatic medullary thyroid carcinoma: A case report
par: Mitra Niafar, et autres
Publié: (2011-01-01)

Educational Case: Medullary Thyroid Carcinoma
par: Carl T. McGary MD, PhD
Publié: (2018-06-01)

Galectin-3 expression in medullary thyroid carcinoma in relation to tumor progression
par: Cvejić Dubravka S., et autres
Publié: (2003-01-01)

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.
par: Grozinsky-Glasberg, S, et autres
Publié: (2008)

Evaluation of the Association between Serotonin and Bone Mineral Density in Patients with Neuroendocrine Tumors
par: Den Gupta, P, et autres
Publié: (2011)

Mixed Medullary-Follicular Carcinoma of the Thyroid
par: Maasumeh Tohidi, et autres
Publié: (2013-01-01)

Remarkable Calcifications in Medullary Thyroid Carcinoma
par: Mukut Roy, et autres
Publié: (2014-05-01)

Update of pathology in medullary thyroid carcinoma
par: LIU Zhiyan, YU Yaling, KAKUDO Kennichi
Publié: (2023-11-01)

Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma
par: Sergio PA Toledo, et autres
Publié: (2009-01-01)

Papillary variant of medullary carcinoma thyroid
par: Saumya Shukla, et autres
Publié: (2014-01-01)

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
par: Grozinsky-Glasberg, S, et autres
Publié: (2008)

Diagnosis and treatment of medullary thyroid carcinoma: A case report
par: Xin Nie, et autres
Publié: (2023-11-01)

An Unusual Variant of Medullary Carcinoma of Thyroid – A Case Report
par: R. Thamil Selvi, et autres
Publié: (2011-07-01)

A case report of simultaneous medullary and papillary carcinoma of thyroid
par: Ziaolhagh Reza, et autres
Publié: (2021-04-01)

Medullary carcinoma of thyroid: Case report and a review of literature
par: Ratna Priya, et autres
Publié: (2016-01-01)

Combined treatment and survival of medullary thyroid carcinoma patients
par: Baranauskas Zenonas, et autres
Publié: (2010-08-01)

Medullary Thyroid Carcinoma and Papillary Thyroid Carcinoma in the Same Patient as a Collision Tumour
par: Oguz Dikbas, et autres
Publié: (2019-01-01)

Progress of study on medullary thyroid carcinoma with serum calcitonin-negative and large mass
par: LI Rui, LIU Zhuoran, YAN Jiqi
Publié: (2022-06-01)

Mixed Medullary and Follicular Thyroid Carcinoma (MMFTC)
par: Hasnaini Hasnaini, et autres
Publié: (2020-11-01)

Calcitonin receptor expression in medullary thyroid carcinoma
par: Virginia Cappagli, et autres
Publié: (2017-09-01)

Diagnosis and treatment of medullary thyroid carcinoma-an update
par: CHEN Chengkun, GUO Bomin, DENG Xianzhao, WU Bo, FAN Youben
Publié: (2022-06-01)